These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22222504)

  • 1. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
    Blin P; Lassalle R; Dureau-Pournin C; Ambrosino B; Bernard MA; Abouelfath A; Gin H; Le Jeunne C; Pariente A; Droz C; Moore N
    Diabetologia; 2012 Mar; 55(3):644-53. PubMed ID: 22222504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data.
    van Staa TP; Patel D; Gallagher AM; de Bruin ML
    Diabetologia; 2012 Mar; 55(3):654-65. PubMed ID: 22127412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
    Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
    Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of insulin glargine on the risk of breast cancer.
    Suissa S; Azoulay L; Dell'Aniello S; Evans M; Vora J; Pollak M
    Diabetologia; 2011 Sep; 54(9):2254-62. PubMed ID: 21614572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
    Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
    Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.
    Fagot JP; Blotière PO; Ricordeau P; Weill A; Alla F; Allemand H
    Diabetes Care; 2013 Feb; 36(2):294-301. PubMed ID: 22966091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
    Colhoun HM;
    Diabetologia; 2009 Sep; 52(9):1755-65. PubMed ID: 19603149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
    Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
    PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
    Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
    Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.
    Habel LA; Danforth KN; Quesenberry CP; Capra A; Van Den Eeden SK; Weiss NS; Ferrara A
    Diabetes Care; 2013 Dec; 36(12):3953-60. PubMed ID: 24170756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study.
    Chang CH; Toh S; Lin JW; Chen ST; Kuo CW; Chuang LM; Lai MS
    PLoS One; 2011; 6(6):e21368. PubMed ID: 21738645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
    Currie CJ; Poole CD; Gale EA
    Diabetologia; 2009 Sep; 52(9):1766-77. PubMed ID: 19572116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients.
    Morden NE; Liu SK; Smith J; Mackenzie TA; Skinner J; Korc M
    Diabetes Care; 2011 Sep; 34(9):1965-71. PubMed ID: 21775752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.
    Stürmer T; Marquis MA; Zhou H; Meigs JB; Lim S; Blonde L; Macdonald E; Wang R; Lavange LM; Pate V; Buse JB
    Diabetes Care; 2013 Nov; 36(11):3517-25. PubMed ID: 23877991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients.
    Monami M; Colombi C; Balzi D; Dicembrini I; Giannini S; Melani C; Vitale V; Romano D; Barchielli A; Marchionni N; Rotella CM; Mannucci E
    Diabetes Care; 2011 Jan; 34(1):129-31. PubMed ID: 20980415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
    Johnson JA; Majumdar SR; Simpson SH; Toth EL
    Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin analogues and cancer risk: the emergence of second-generation studies.
    Renehan AG
    Diabetologia; 2012 Jan; 55(1):7-9. PubMed ID: 22033621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined randomised controlled trial experience of malignancies in studies using insulin glargine.
    Home PD; Lagarenne P
    Diabetologia; 2009 Dec; 52(12):2499-506. PubMed ID: 19756478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin.
    Lim S; Stember KG; He W; Bianca PC; Yelibi C; Marquis A; Stürmer T; Buse JB; Meigs JB
    PLoS One; 2014; 9(10):e109433. PubMed ID: 25329887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.